HPV single-dose vaccination: Impact potential, evidence base and further evaluation

Stanley, Margaret; Dull, Peter

doi:10.1016/j.vaccine.2018.02.076

Cited by 19 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A reason that the observed impacts described above may be larger than anticipated, given the difficulties experienced with achieving high coverage with three doses in most countries, is if one or two doses are providing partial or complete protection. This seems increasingly plausible on the basis of immunological, post hoc trial and emerging observational data consistent with a significant protective effect of less than three doses [8].…”

Section: Impact On Genital Wartsmentioning

confidence: 99%

Impact of HPV vaccination: Achievements and future challenges

Brotherton

2019

Papillomavirus Research

View full text Add to dashboard Cite

Section: Impact On Genital Wartsmentioning

confidence: 99%

Impact of HPV vaccination: Achievements and future challenges

Brotherton

2019

Papillomavirus Research

View full text Add to dashboard Cite

“…Likewise, further work will be worth doing to verify if the one dose regime would also be applicable to women above 25 and to adult women in screening ages thus approaching the objective of intervention campaigns in which one visit could be recommended including HPV screen/treat and vaccination. 23…”

Section: The Hpv Faster Conceptmentioning

confidence: 99%

HPV-FASTER: Combined strategies of HPV vaccination and HPV screening towards a one visit for cervical cancer preventive campaigns

Bosch

Robles

2018

Salud Publica Mex

View full text Add to dashboard Cite

show abstract

“…This approach was also deemed most likely to confer the longest duration of protective immunity, compared to shorter dose schedules. 14 Therefore, in 2009, the WHO recommended that countries adopt a three-dose schedule for their National Immunization Programs. 15 Trials of the three-dose HPV vaccine schedule have demonstrated consistently high levels of efficacy and effectiveness.…”

mentioning

confidence: 99%

Key ethical considerations to guide the adjudication of a single-dose HPV vaccine schedule

Shadab¹,

Lavery

McFadden³

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

There is a high burden of human papillomavirus (HPV) associated cancers in low-and middle-income countries (LMICs). Reducing the recommended dosing schedule from two doses to one makes the vaccine schedule logistically simpler and lowers the cost. This could make the distribution of the current vaccine supply more equitable and lead to the protection of more people. However, the clinical trials studying the efficacy of a single-dose schedule have not yet delivered final results. Against this background, the question is whether a single-dose HPV vaccine recommendation is appropriate now, and if so, what are the ethical considerations of such a recommendation? We developed three ethical recommendations: (1) adopt a holistic view of evidence to justify policy decisions; (2) prioritize the reduction in global disparities in decision-making at all levels; and (3) be transparent in the reporting of how key stakeholder interests have shaped the collection and interpretation of the evidence, and ultimate decisions. The complex discussion regarding the HPV single-dose vaccine schedule highlights the need for in-depth engagement globally to improve our understanding of country-specific contexts, and how those contexts influence decisions regarding the HPV vaccine single-dose recommendation.

show abstract

HPV single-dose vaccination: Impact potential, evidence base and further evaluation

Cited by 19 publications

References 18 publications

Impact of HPV vaccination: Achievements and future challenges

Impact of HPV vaccination: Achievements and future challenges

HPV-FASTER: Combined strategies of HPV vaccination and HPV screening towards a one visit for cervical cancer preventive campaigns

Key ethical considerations to guide the adjudication of a single-dose HPV vaccine schedule

Contact Info

Product

Resources

About